Login or Create Account

Resources with keywords: mRNA

Training Tools & Resources
SARS-CoV-2/COVID-19


Safety Monitoring of mRNA COVID-19 Vaccine Third Doses Among Children Aged 6 Months–5 Years — United States, June 17, 2022–May 7, 2023 (Website, Publication)
CDC/MMWR
9 June 2023

Hause AM, Marquez P, Zhang B, et al.

keywords: children, covid-19, mRNA, vaccination, vaccines
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 2023 (Website, Regulatory)
CDC/MMWR
3 February 2023

Link-Gelles R, Ciesla AA, Roper LE, et al.

keywords: covid-19, mRNA, omicron, vaccines
Effectiveness of COVID-19 mRNA Vaccination in Preventing COVID-19–Associated Hospitalization Among Adults with Previous SARS-CoV-2 Infection — United States, June 2021–February 2022 (NEW 5/6, Website, Publication)
CDC/MMWR
15 April 2022

Plumb ID, Feldstein LR, Barkley E, et al.

keywords: covid-19, hospitalization, mRNA, vaccines
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 (Website, Publication)
CDC/MMWR
18 February 2022

Ferdinands JM, Rao S, Dixon BE, et al.

keywords: covid-19, Delta, mRNA, omicron
Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021 (NEW 11/2, Website, Publication)
CDC/MMWR
5 November 2021

Olson SM, Newhams MM, Halasa NB, et al.

keywords: covid-19, mRNA, vaccine-induced immunity, vaccines
What’s the research progress of mRNA vaccines for infectious diseases?
Medical Trend
24 October 2021
keywords: mRNA, vaccines, zika virus
Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses (NEW 8/3, Website, Publication)
JAMA
23 July 2021

Ilies Benotmane, Gabriela Gautier, Peggy Perrin, et al

keywords: covid-19, mRNA, serology, vaccines

typos, broken links, suggestions/corrections

Not a member and would like updates and notifications?

Quick Links: HOME | ABOUT | MEMBERSHIP | EDUCATION | CALENDAR | RESOURCES | CREDENTIALS

Also from ABSA International: Applied Biosafety: Journal of ABSA International | ABSA Job Board | BiosafetyBuyersGuide.org | Annual Biosafety and Biosecurity Conference | International Biosecurity Symposium | USDA ARS International Biosafety & Biocontainment Symposium | Biosafety & Biosecurity Training Course (BBTC®) | Principles & Practices of Biosafety® | my.ABSA.org | Risk Group Database | LAI Database | connect.ABSA.org

ABSA International
1200 Allanson Road, Mundelein, IL 60060-3808
1-866-425-1385 (toll free) or 847-949-1517
info@absa.org | Contact ABSA

Copyright © ABSA International. All Rights Reserved. Privacy Policy

ABSA International does not endorse, promote, review, or warrant the accuracy of the products and services offered by those parties who link to the ABSA International website. The links are merely provided as a convenience to the visitors of this site, and ABSA International may or may not be compensated for permitting the link to be displayed on this page.

Go to Top